Jun 23, 2020 / 01:00PM GMT
George Farmer - BMO Capital Markets Equity Research - Analyst
Good morning. I'm George Farmer, Senior Biotechnology Analyst with BMO Capital Markets. Thank you all for joining us this morning. Our next company that we'll be highlighting today is Agios. With me today is the CEO, Jackie Fouse. I'm very pleased to have joining with us to talk about the company in our fireside chat, so to speak.
Jackie, welcome. So happy to have you join us. Why don't we kick off with your big strategic 2025 vision that you presented at the beginning of the year, just kind of remind us where you see Agiosâ heading. And then we can dig into some pipeline specifics.
Jacqualyn A. Fouse - Agios Pharmaceuticals, Inc. - CEO & Director
Great. Thanks so much. Thanks for having me, for having us, the company. So good morning, everybody.
So real quickly, just in terms of our strategic priorities of where we are today in our 2025 vision, which is very much still on track despite the virus pandemic situation. So as many of you probably know, we have 2 IDH inhibitors that
Agios Pharmaceuticals Inc at BMO Capital Markets Prescription for Success Healthcare Conference (Virtual) Transcript
Jun 23, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers